Bergenbio Asa Is A Clinical Stage Biopharmaceutical Company Based In Bergennorwaywith A Subsidiary In Oxfordukthe Company Focuses On Developing Innovative Therapeutics That Target The Axl Kinasea Receptor Involved In Aggressive Diseases Such As Cancer And Severe Respiratory Infectionsbergenbio Aims To Address Critical Mechanisms Like Cancer Metastasisimmune Evasionand Drug Resistancewhich Contribute Significantly To Cancer Related Deaths The Company S Lead Productbemcentinibis An Orally Bioavailable Axl Inhibitor Designed For Once Daily Dosingit Is Currently In Clinical Trials For Stk11 Mutated Non Small Cell Lung Cancer And Is Also In Preclinical Development For Severe Respiratory Infectionsbergenbio S Research Emphasizes The Potential Of Axl Inhibition To Disrupt Disease Progression And Restore Immune Functionthe Company Collaborates With Clinical Sites And Experts To Enhance Trial Design And Therapeutic Strategiestargeting High Unmet Need Oncology Indications And Emerging Infectious Disease Threats
